PPARG and Insulin resistance: Peroxisome proliferator-activated receptor gamma (PPARγ) is the target of clinical insulin sensitizers, which can protect diabetes and related complication, such as endothelial cell injury and vascular endothelial insulin resistance (IR) induced by high glycemic (Zhang et al., 2015).